港股異動丨博安生物瞬間飆升超200%
博安生物(6955.HK)尾盤拉昇,一度飆漲203%至25港元,成交額放大至2億港元。華安證券近日發研報稱,博安生物在生物類似藥領域展現出顯著的穩定創收能力與國際化佈局優勢。公司已在國內獲批貝伐珠單抗和兩款地舒單抗(BA6101和BA1102)生物類似藥,同時該兩款地舒單抗的歐、美、日國際多中心Ⅲ期臨牀試驗於2024年1月完成所有受試者入組,計劃覆蓋全球市場並在海外核心市場進行授權合作。度拉糖肽(BA5101)和阿柏西普(BA9101)生物類似藥在國內處於BLA審評階段,且前者在美國獲批臨牀,研發進度在同類產品中領先。通過構建符合中、美、歐GMP標準的生產體系(商業化產能達9000L),博安生物成功推動地舒單抗等產品搶佔原研藥專利到期的市場窗口期,使biosimilar業務成爲公司盈利的基礎驅動力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.